Open access

468 Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 status
Sruthi Ravindranathan, Xiaoguang Wang, Daniel J Chin, Su-Yi Tseng, Scott Klakamp, Kate Widmann, Varun Kapoor, Vladimir Vexler, Patricia Keegan, Sheng Yao, Sanjay D Khare, Theresa LaVallee, Narendiran Rajasekaran

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A522-A526; DOI: 10.1136/jitc-2023-SITC2023.0468
469 Combining a safe PI3Kd inhibitor with chemotherapy and anti-PD1 in immunotherapy-refractory NSCLC: a proof-of-concept study to allow clinical trial design
Chiara Riganti, Giorgio Scagliotti, Silvia Novello, Fabrizio Tabbo, Luisella Righi, Laurence Neff, Michael Lahn, Lars Van der Veen, Giusy Di Conza

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A527; DOI: 10.1136/jitc-2023-SITC2023.0469
470 MNRR1 inhibition, a potential therapeutic avenue for breast cancer
Fiona Samson, Neeraja Purandare, Siddhesh Aras

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A528-A529; DOI: 10.1136/jitc-2023-SITC2023.0470
471 CD47 blockade as a targeted immune oncology agent in head and neck squamous cell carcinoma model
Riyam Al Msari, Robert Saddawi-Konefka, Joseph Califano, Shiqi Tang, Chad Phillips

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A530; DOI: 10.1136/jitc-2023-SITC2023.0471
472 Anti-VEGF treatment amplifies immune checkpoint inhibitor induced immune responses by targeting B and regulatory T cells
Mohamed-Reda Benmebarek, Cihan Oguz, Benjamin Ruf, Yuta Myojin, Patrick Huang, Chi Ma, Kylynda Bauer, Marina Villamor Paya, Matthias Seifert, Justin Lack, Firouzeh Korangy, William Telford, Tim F Greten

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A531; DOI: 10.1136/jitc-2023-SITC2023.0472
473 LAE113, a novel TIGIT/PVRIG bispecific antibody for the treatment of cancer
Yan Chen, Xue Li, Ling Jiang, Xiang-Ju Justin Gu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A532; DOI: 10.1136/jitc-2023-SITC2023.0473
474 Intratumoral CTLA-4-targeting INTASYL™ self-delivering RNAi enhances tumor control in combination with systemic anti-PD-1 antibody therapy in vivo suggesting a strategy to mitigate irSAEs
Benjamin Cuiffo, Dingxue Yan, Andrew Boone, Brianna Rivest, Melissa Maxwell, James Cardia

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A533; DOI: 10.1136/jitc-2023-SITC2023.0474
475 Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells
Kelsey E Sivick Gauthier, Dana Piovesan, Amber E de Groot, Amy E Anderson, Rebecca D Ray, Nina K Serwas, Soonweng Cho, Amita Patnaik, Paul Foster, Casey G Mitchell, Hema Singh, Xiaoning Zhao, Lisa Seitz, Nigel Walker, Matthew J Walters

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A534; DOI: 10.1136/jitc-2023-SITC2023.0475
476 Development of a flow cytometric receptor occupancy assay for clinical analysis of immune checkpoint inhibitor therapeutics
Haoting Hsu, Jessica Pearl, Megan Richardson, Brandon Walling, Mara Gilardi, Michael Ritchie, Karin Abarca Heidemann, Maria Mancini

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A535; DOI: 10.1136/jitc-2023-SITC2023.0476
477 A novel antibody targeting human monocyte-intrinsic PD-L1 promotes immune stimulatory functions of monocytes for antitumor immunity
Michelle Hsu, Xin Liu, Ying Li, Jacob Hirdler, Fabrice Lucien-Matteoni, Haidong Dong

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A536; DOI: 10.1136/jitc-2023-SITC2023.0477

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages